Morning Overview on MSN
Disabling NFIL3 via CRISPR kept engineered CAR T-cells from hitting exhaustion, prolonging tumor control in animal models
Researchers at Columbia University’s Sadelain lab and University Hospital Tubingen used CRISPR gene editing to knock out the ...
By Nancy Lapid June 5 (Reuters) - We also highlight a series of promising CAR-T studies in a variety of hard-to-treat ...
Morning Overview on MSN
Disabling a single protein called NFIL3 kept CAR T-cells fighting tumors longer in a screen of 400 transcription factors
Researchers screening roughly 400 transcription factors found that disabling a single protein, NFIL3, allowed CAR T-cells to ...
A pioneering clinical trial has successfully enabled two patients with end-stage kidney disease to receive previously ...
Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients ...
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.
A new study reveals a possible way to make CAR T-cell therapy more durable and effective by targeting a single ...
Researchers from the Icahn School of Medicine at Mount Sinai have discovered a promising new way to improve CAR-T cell ...
The cost of CAR T-cell therapy means that the highly effective cancer treatment is unavailable in many parts of the world.
Researchers found that lowering MHC I can expose cancerous or foreign cells to CD4+ T cell attack, reshaping assumptions ...
CAR T-cell therapy has been hugely successful in treating certain types of tumours, and stiffening up cancer cells beforehand could make it even more effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results